LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Gilead Sciences Inc.

Slēgts

SektorsVeselības aprūpe

112.97 0.41

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

112.5

Max

113.03

Galvenie mērījumi

By Trading Economics

Ienākumi

645M

2B

Pārdošana

414M

7.1B

P/E

Sektora vidējais

22.649

35.724

Dividenžu ienesīgums

2.72

Peļņas marža

27.68

Darbinieki

17,600

EBITDA

769M

3.4B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+11.11% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.72%

3.09%

Nākamais dividenžu datums

2025. g. 29. sept.

Nākamais Ex dividenžu datums

2025. g. 15. sept.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-804M

142B

Iepriekšējā atvēršanas cena

112.56

Iepriekšējā slēgšanas cena

112.97

Ziņu noskaņojums

By Acuity

24%

76%

19 / 372 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Gilead Sciences Inc. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 21. aug. 13:45 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Interius BioTherapeutics for $350 Million

2025. g. 7. aug. 20:59 UTC

Peļņas

Gilead Sciences Upgrades Guidance After 2Q Results Top Views

2025. g. 24. apr. 20:17 UTC

Peļņas

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

2025. g. 21. aug. 12:35 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences Sees Transaction With Interius Cutting 2025 Adjusted EPS by 23c-25c >GILD

2025. g. 21. aug. 12:31 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Interius is Private Biotechnology Company Developing In-Vivo CAR Therapeutics >GILD

2025. g. 21. aug. 12:31 UTC

Iegādes, apvienošanās, pārņemšana

Gilead's Kite to Buy Interius BioTherapeutics for $350 Million >GILD

2025. g. 21. aug. 12:30 UTC

Iegādes, apvienošanās, pārņemšana

Kite To Acquire Interius BioTherapeutics To Advance In Vivo Platform >GILD

2025. g. 8. aug. 20:28 UTC

Peļņas

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

2025. g. 8. aug. 17:27 UTC

Peļņas

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

2025. g. 8. aug. 12:03 UTC

Peļņas

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Firefly -- Barrons.com

2025. g. 8. aug. 11:13 UTC

Peļņas

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Firefly -- Barrons.com

2025. g. 7. aug. 21:13 UTC

Peļņas

Gilead Earnings Beat Estimates, But All Eyes Are On New HIV Shot -- Barrons.com

2025. g. 7. aug. 20:44 UTC

Peļņas

Gilead Sciences Ups Guidance After 2Q Results Top Views

2025. g. 7. aug. 20:26 UTC

Peļņas

Gilead Sciences: Liver Disease Portfolio Sales Decreased 4% to $795M in 2Q >GILD

2025. g. 7. aug. 20:26 UTC

Peļņas

Gilead Sciences: 2Q Descovy Sales Increased 35% to $653M >GILD

2025. g. 7. aug. 20:25 UTC

Peļņas

Gilead Sciences: HIV Pdt Sales Increased 7% to $5.1 B in 2Q >GILD

2025. g. 7. aug. 20:24 UTC

Peļņas

Gilead Sciences: 2Q Biktarvy Sales Increased 9% Yr-Over-Yr to $3.5 B >GILD

2025. g. 7. aug. 20:22 UTC

Peļņas

Gilead Sciences 2Q Adj EPS $2.01 >GILD

2025. g. 7. aug. 20:22 UTC

Peļņas

Gilead Sciences 2Q Net $1.96B >GILD

2025. g. 7. aug. 20:22 UTC

Peļņas

Gilead Sciences Sees FY EPS $5.85-EPS $6.15 >GILD

2025. g. 7. aug. 20:22 UTC

Peļņas

Gilead Sciences 2Q Rev $7.1B >GILD

2025. g. 7. aug. 20:22 UTC

Peļņas

Gilead Sciences 2Q Total Liver Disease Sales $211M >GILD

2025. g. 7. aug. 20:22 UTC

Peļņas

Gilead Sciences Sees FY Adj EPS $7.95-Adj EPS $8.25 >GILD

2025. g. 7. aug. 20:22 UTC

Peļņas

Gilead Sciences 2Q EPS $1.56 >GILD

2025. g. 27. apr. 11:00 UTC

Top Ziņas

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

2025. g. 24. apr. 20:08 UTC

Peļņas

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences 1Q Rev $6.67B >GILD

2025. g. 24. apr. 20:02 UTC

Peļņas

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

Salīdzinājums

Cenas izmaiņa

Gilead Sciences Inc. Prognoze

Cenas mērķis

By TipRanks

11.11% augšup

Prognoze 12 mēnešiem

Vidējais 125.52 USD  11.11%

Augstākais 143 USD

Zemākais 98 USD

Pamatojoties uz 23 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Gilead Sciences Inc. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

23 ratings

18

Pirkt

5

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

97.33 / 103.17Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bearish Evidence

Ilgtermiņā

Weak Bullish Evidence

Noskaņojums

By Acuity

19 / 372 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.